Related Experiment Video
Updated: Jun 24, 2025
08:58
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
Published on: April 18, 2025
451
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An
Mario Tumbarello1,2, Francesca Raffaelli3, Maddalena Giannella4
1Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Open Forum Infectious Diseases
|June 10, 2024
Summary
Meropenem-vaborbactam effectively treats KPC-producing Klebsiella pneumoniae infections, including those resistant to other drugs. Early administration within 48 hours improves survival rates in severe cases.
Area of Science:
- Infectious Diseases
- Antimicrobial Resistance
- Clinical Pharmacology
Background:
- Meropenem-vaborbactam offers a new treatment for KPC-producing Klebsiella pneumoniae (KPC-Kp) infections.
- This includes KPC-Kp strains resistant to ceftazidime-avibactam.
Purpose of the Study:
- To analyze the real-world use and outcomes of meropenem-vaborbactam in KPC-Kp infections.
- To identify factors associated with 30-day mortality in patients treated with meropenem-vaborbactam.
Main Methods:
- Retrospective analysis of observational data from 19 Italian hospitals.
- Included 342 adult patients with KPC-Kp infections treated with meropenem-vaborbactam for ≥24 hours.
- Used crude and propensity-weighted Cox regression models to assess mortality risk factors.
Main Results:
- The 30-day mortality rate was 31.6%.
- Independent predictors of mortality included septic shock, high Charlson comorbidity index, dialysis, and COVID-19.
- Early meropenem-vaborbactam administration (within 48 hours) was associated with lower mortality.
Conclusions:
- Meropenem-vaborbactam demonstrates efficacy in severe KPC-Kp infections.
- The drug is effective even when used as monotherapy.
- Early treatment initiation is crucial for improving patient outcomes.
Keywords:
KPC-producing Klebsiella pneumoniaebloodstream infectioncarbapenemasesceftazidime-avibactam resistancemeropenem-vaborbactamMore Related Videos
Related Concept Videos
01:28Pneumonia IV: Management
322
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
322
01:24Kaplan-Meier Approach
129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129